Deutsche Bank AG Decreases Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Deutsche Bank AG lowered its position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 47.3% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 6,214 shares of the company's stock after selling 5,583 shares during the period. Deutsche Bank AG's holdings in Medpace were worth $2,064,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in MEDP. R Squared Ltd acquired a new stake in shares of Medpace in the fourth quarter valued at about $30,000. SBI Securities Co. Ltd. purchased a new stake in Medpace during the 4th quarter valued at about $31,000. Jones Financial Companies Lllp raised its holdings in Medpace by 2,750.0% in the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock valued at $38,000 after acquiring an additional 110 shares during the last quarter. Lindbrook Capital LLC lifted its stake in Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock worth $45,000 after purchasing an additional 29 shares in the last quarter. Finally, Assetmark Inc. boosted its holdings in shares of Medpace by 20.1% during the 4th quarter. Assetmark Inc. now owns 173 shares of the company's stock worth $57,000 after purchasing an additional 29 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.

Medpace Stock Performance

Shares of Medpace stock traded up $3.94 on Tuesday, reaching $298.83. The company had a trading volume of 73,425 shares, compared to its average volume of 353,355. The firm's 50 day moving average price is $301.18 and its two-hundred day moving average price is $326.12. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $459.77. The firm has a market cap of $8.59 billion, a PE ratio of 23.66, a PEG ratio of 3.81 and a beta of 1.55.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.06 by $0.61. Medpace had a return on equity of 51.48% and a net margin of 19.17%. The company had revenue of $558.57 million for the quarter, compared to analyst estimates of $528.38 million. During the same quarter in the previous year, the company earned $3.20 earnings per share. As a group, sell-side analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Insider Buying and Selling

In related news, Director Fred B. Davenport, Jr. sold 1,712 shares of Medpace stock in a transaction that occurred on Thursday, April 24th. The shares were sold at an average price of $301.82, for a total value of $516,715.84. Following the completion of the transaction, the director now owns 2,998 shares in the company, valued at approximately $904,856.36. The trade was a 36.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 20.30% of the stock is owned by corporate insiders.

Analyst Ratings Changes

MEDP has been the subject of several recent research reports. Leerink Partners started coverage on Medpace in a report on Monday, March 24th. They issued a "market perform" rating and a $330.00 price target for the company. TD Cowen downgraded Medpace from a "buy" rating to a "hold" rating and cut their target price for the stock from $370.00 to $328.00 in a research note on Monday, April 14th. Truist Financial lowered their price target on shares of Medpace from $333.00 to $300.00 and set a "hold" rating on the stock in a research report on Wednesday, April 23rd. Robert W. Baird dropped their price objective on shares of Medpace from $340.00 to $313.00 and set a "neutral" rating for the company in a report on Wednesday, April 23rd. Finally, William Blair reaffirmed a "market perform" rating on shares of Medpace in a research note on Tuesday, April 22nd. Eleven investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $349.30.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.